These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2528 related articles for article (PubMed ID: 33508919)

  • 1. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 4. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 7. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
    Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
    Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
    Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ; Yuan P; Zhai JN; Yao YF; Tan LX; Li ZW; Zhang XY; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):684-693. PubMed ID: 39004983
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 15. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
    Feng D; Leong M; Li T; Chen L; Li T
    World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 127.